MTX vs RHI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MTX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MTX and RHI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MTX and RHI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Minerals Technologies Inc. (NYSE: MTX) is a global specialty minerals company built originally out of Pfizer's minerals unit. It is one of the largest producers of precipitated calcium carbonate (PCC) and the world's largest bentonite producer, and it organizes its business into two segments: Consumer & Specialties (household and personal care products such as cat litter, personal care, fabric care, edible-oil purification, plus specialty additives) at roughly 53% of sales, and Engineered Solutions (high-temperature refractory technologies and environmental and infrastructure products) at roughly 47%. The company sells into paper, packaging, construction, automotive, foundry, steel, and consumer markets across more than 35 countries.

Full MTX guide

Robert Half Inc. is one of the largest specialized talent-solutions firms in the world, placing contract and permanent professionals in finance, accounting, technology, legal, administrative, and creative roles. It operates through two engines: its staffing business (contract talent and permanent placement) and Protiviti, a global business-consulting and internal-audit arm where technology consulting (modernization, data, and cyber) is now the largest and fastest-growing piece. The company earns fees on placements and consulting engagements, so its results swing closely with corporate hiring appetite and project spending.

Full RHI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MTX drivers: Diversified specialty-minerals franchise; Return to growth and margin recovery.
• RHI drivers: Cyclical staffing recovery; Protiviti and technology consulting.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the talc litigation itself: the reorganization plan must be confirmed and funded, and a large charge (around $290 million booked in 2026) already pressures reported results, turning the second quarter into a GAAP net loss of ~$184 million, with the possibility of adverse rulings or higher-than-expected claim funding. For RHI, the core risk is prolonged weakness in white-collar hiring, which keeps staffing revenue and permanent placement under pressure and delays any earnings recovery.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MTX if you believe its drivers more; RHI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MTX and RHI guides.

MTX. With the talc charge pushing trailing GAAP earnings negative, there is no meaningful trailing P/E; on forward estimates (~$6.88 of 2027 EPS) MTX trades at roughly 9 times earnings, about 0.9 times sales and ~7 times EV/EBITDA, a clear discount to the broader chemicals and materials group. That discount reflects the market pricing in talc-litigation uncertainty and a slower top line rather than weak operations, since operating margin is ~13.6% and free cash flow over the trailing year was ~$393 million. The valuation gap is still the crux of the debate, and third quarter results around October 29, 2026 will show whether growth reaccelerates from the second quarter's ~3.7%.

RHI. As of October 16, 2026, Robert Half trades near 29x trailing earnings because those earnings sit near a cyclical low; on 2027 consensus EPS of ~$1.97 the multiple drops to about 17x. The ~6.9% dividend yield rests on a payout of roughly twice trailing earnings, so coverage depends on the recovery analysts are modeling. The Q3 2026 report on October 22 (consensus EPS ~$0.47) is the next data point.

Headline figures (approximate, October 2026): MTX shows revenue (ttm) ~$2.15B, q2 2026 revenue ~$548M (up ~3.7% YoY), q2 2026 adjusted eps ~$1.60 (vs ~$1.63 est.), operating margin (ttm) ~13.6%; RHI shows revenue (ttm) ~$5.29B, q2 2026 revenue ~$1.34B (down ~2.4% YoY), net income (ttm) ~$115M (~2% margin), eps (ttm) ~$1.15 (Q2 2026 $0.26, in line).

MTX and RHI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MTX and RHI exposure against your real portfolio. It is not an investment adviser.